SALES COMMENTARY NOT RESEARCH Concordia Genuity
SYR DecQ
- Q4 graphite production of 33kt, ahead of our estimates of 26kt. Variance due mainly to better than expected plant throughput following the fire in the plant during Oct/Nov 2018). Recoveries up QoQ to 70-% (CGe 72%). CY2018 production of 104kt in line with downgraded guidance. Commercial production declared effective 1 January 2019
- Sales – 37kt (CGe 40kt) – DecQ product weighted price lower than SepQ due to product mix (more fines vs higher priced coarse)
- Fines pricing remains under pressure, especially in China
- BAM project – first spherical produced last year, with first purified product expected in Q1 (batch volumes for product qualification). Feasibility completed for 10-40ktpa capacity but capex needs optimising.
- Cash – US$77m (in line).
- Guidance (critical data points)
- CY2019 production ~250kt (CGe 245kt); Q1 – 45-50kt (slightly below our 54kt)
- Cash costs – Q1’19 ~US$550/t trending down to US$400/t over CY19 (CGe CY19 US$603/t)
- Pricing Q1’19 – US$500-600/t. Below our forecast US$680/t, due mainly to product mix (fines vs coarse)
Comments:Key data points relate to CY19 guidance on pricing with commercial productionexpected to deliver greater transparency on costs and pricing. Firm guidanceprovided for 1H, with higher costs and lower pricing showing little margin. SYRexpects both to improve over 2019 – we think an improved product mix is keywith SYR’s bias towards fines graphite leaving it more exposed to lessfavourable market conditions in China.
Wehave a SPEC BUY rating and $3.45 target.
- Forums
- ASX - By Stock
- Ann: Commercial Production Declared at Balama
SALES COMMENTARY NOT RESEARCH Concordia Genuity SYR DecQ Q4...
-
- There are more pages in this discussion • 11 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add SYR (ASX) to my watchlist
(20min delay)
|
|||||
Last
22.3¢ |
Change
-0.003(1.11%) |
Mkt cap ! $232.8M |
Open | High | Low | Value | Volume |
22.5¢ | 23.0¢ | 21.5¢ | $994.9K | 4.504M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
17 | 334841 | 22.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.5¢ | 47512 | 13 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 116062 | 1.070 |
10 | 209299 | 1.065 |
8 | 106613 | 1.060 |
6 | 96647 | 1.055 |
10 | 132219 | 1.050 |
Price($) | Vol. | No. |
---|---|---|
1.075 | 58078 | 4 |
1.080 | 70753 | 4 |
1.085 | 72117 | 5 |
1.090 | 103210 | 6 |
1.095 | 57928 | 2 |
Last trade - 14.54pm 25/11/2024 (20 minute delay) ? |
Featured News
SYR (ASX) Chart |
The Watchlist
ACW
ACTINOGEN MEDICAL LIMITED
Andy Udell, CCO
Andy Udell
CCO
SPONSORED BY The Market Online